Remove 2015 Remove Healthcare Remove Pharmaceutical manufacturing
article thumbnail

Tackling fake pharmaceuticals: an industry united against counterfeit products

European Pharmaceutical Review

Consequently, pharmaceutical manufacturers risk their reputation if impersonating products fail to deliver the expected quality or health impact. Essentially, both counterfeit and falsified medicines pose risks to public health and threaten to undermine the healthcare system and pharmaceutical industry. About the author.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ep. 002 – John Mack Podcast Transcript

Pharma Marketing Network

And do that, you interviewed me back in 2015, for the results book. If you’re a pharmaceutical company or if you’re an agency or even a consultant. If there’s one evolution and I think this is impacting all of healthcare, pharma marketing is pretty specific. John Mack (PG): Yep.

Pharma 52
article thumbnail

Drug pricing increases are disgraceful

World of DTC Marketing

Among the 25 worldwide companies that spend the most on research and development—all more than $5 billion a year—seven are pharmaceutical manufacturers, but eight are automobile or automobile-parts companies with profit margins under 10 percent. Amazon’s operating margin is under 5 percent.

Insurance 181
article thumbnail

FDA warning letters highlight CAPA concerns

European Pharmaceutical Review

Amidst numerous warning letters distributed by the US Food and Drug Administration (FDA) to pharmaceutical manufacturers in recent months, in July this year, the US regulatory body published its analysis on drug product quality in 2022. In subsequent years, up to 2022, half this number or less were issued. Edge Biologicals Inc.,

FDA 98
article thumbnail

Precision Medicine Needs an Overhaul

PM360

Between 2015 and 2021, over a quarter of the drugs approved by the US Food and Drug Administration (FDA) were associated with specific biomarkers. When we talk about the future of precision medicine, we envision a harmonious union of healthcare and technology. That’s how money is saved and quality of life (QOL) is improved.